Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Montreux Equity Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Montreux Equity Partners

Montreux Equity Partners

Operating

Montreux Equity Partners: A private investment firm, fueling the growth of tomorrow's leading companies since 1993.

Location
San Francisco, CA, US
Founded
1993
Firm
Compare
Portfolio
Employees
Website

Montreux Equity Partners focuses on growth capital investments in high-growth, commercial-stage companies across various sectors. The firm typically invests in Series A to Series D rounds, with a particular emphasis on Series B investments. Montreux targets companies with category-leading products, technologies, and services, aiming to accelerate their scale and growth.

Notable portfolio companies include Glaukos, Pulmonx, and TigerConnect. Montreux's investment philosophy centers on fueling the growth of tomorrow's leading companies, a strategy they have pursued since their founding in 1993. The firm differentiates itself by offering strategic support to help portfolio companies achieve rapid growth and market leadership.

Montreux Equity Partners - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments35
Current Portfolio Count16
Total Portfolio Exits1

Top Investment Stages

Series B8 (27.6%)
Series D6 (20.7%)
Series A5 (17.2%)
Series C5 (17.2%)
Series Unknown5 (17.2%)

Stage Mix

Series B 28%Series D 21%Series A 17%Series C 17%Series Unknown 17%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Tebra logo

Tebra

KEO World logo

KEO World

FinPay logo

FinPay

TigerConnect logo

TigerConnect

Pulmonx logo

Pulmonx

Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

Pure Life Renal logo

Pure Life Renal

Epirus Biopharmaceuticals logo

Epirus Biopharmaceuticals

Glaukos logo

Glaukos

Avantis Medical Systems logo

Avantis Medical Systems

Moksha8 logo

Moksha8

Novostent logo

Novostent

Domain Associates logo

Domain Associates

Sequel Pharmaceuticals logo

Sequel Pharmaceuticals

KFx Medical logo

KFx Medical

Bayhill Therapeutics logo

Bayhill Therapeutics

NeurogesX logo

NeurogesX

Just Kratom Store logo

Just Kratom Store

Montreux Equity Partners - Classification

Also Known As
  • Montreux Equity Partners Inc
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified